Introduction
The incidence of ovarian cancer has recently been increasing and has become the largest cause of death from gynecological neoplasia. 1 Because of the lack of effective screening strategies and the absence of symptoms with early stage diseases, almost 60% of ovarian cancer patients are found at stages III and IV. For these advanced ovarian cancer patients, aggressive surgery and combination chemotherapy utilizing platinum-based drugs are applied. In recent years, marked improvement of prognosis of advanced ovarian cancer by a combination chemotherapy with cisplatin and paclitaxel was shown, but the long-term prognosis is still unsatisfactory. 2 Peritoneal dissemination is the most frequent progression pathway of ovarian cancer. 3, 4 Accordingly, control of peritoneal dissemination is a key step to improve the prognosis of advanced ovarian cancer.
NK4 is a large part of the ␣-chain of hepatocyte growth factor (HGF), containing four kringle domains. 5 NK4 has been reported to inhibit cancer cell growth and migration both in vitro and in vivo. [5] [6] [7] [8] [9] To clarify the function of NK4 and establish a novel gene therapy approach for ovarian cancer, we transferred NK4-expression plasmid into an ovarian cancer cell line and investigated its effects on both in vitro migration and in vivo tumor dissemination.
Results

Expression of NK4 in HRA cells
The NK4 expression plasmid vector pCMV-NK4-IRESbsr, and the control vector pCMV-luciferase (LUC)-IRESbsr ( Figure 1 ) were transfected into HRA cells, respectively. As shown in Figure 2 , NK4 expression was detected by Western blotting at the position corresponding to a molecular weight of 67 kDa in the culture supernatant of HRA/NK4, while no NK4 expression was detected in the culture supernatant of parent HRA or HRA/LUC.
In vitro cell growth kinetics
The growth curves of HRA, HRA/LUC and HRA/NK4 are denoted in Figure 3 , showing no significant differences among the three groups. Therefore, expression of the NK4 gene did not affect the cell growth in vitro.
In vitro scratch wound healing assay
The effects of NK4 expression on cell migration in vitro are shown in Figure 4 . NK4-expressing cells exhibited 
In vivo tumor growth
Based on the in vitro experiments, we tested the effect of NK4 expression on tumor growth in vivo. As shown in Figure 5 , there were no differences in the growth rate among the three groups. The estimated tumor doubling times were 4.4, 4.3 and 4.3 days in HRA, HRA/LUC-, and HRA/NK4-derived tumors, respectively. Therefore, we concluded that the NK4 expression did not affect the tumor growth.
In vivo peritoneal dissemination
We investigated the consequences of NK4 expression on peritoneal dissemination in vivo. The number of peritoneal tumors 8 days after intraperitoneal injection of HRA/NK4 was 30 ± 13/mouse, which was significantly decreased compared with those in mice injected HRA (104 ± 38/mouse) and HRA/LUC (114 ± 35/mouse) (P Ͻ 0.01, Figure 6 and 7). Therefore, the NK4 expression inhibited peritoneal dissemination.
Survival rate of mice injected with cancer cells
Finally, the outcome of NK4 expression on the survival rate of mice was evaluated following intraperitoneal injection with cancer cells. In the mice injected with HRA and HRA/LUC, marked ascites accumulation was observed about 7 days after injection, and all mice died within 15 days. In contrast, in the mice injected with HRA/NK4, ascites formation was inhibited and the survival time was significantly prolonged (P Ͻ 0.01, Figure  8 ). Therefore, the expression of the NK4 extended the survival of mice intraperitoneally injected with HRA/NK4.
Discussion
Hepatocyte growth factor (HGF) is a heterodimeric molecule that plays a key role in the regulation of migration, invasion and angiogenesis in cancer. [10] [11] [12] [13] HGF is composed of an ␣-chain, containing the N-terminal hairpin domain and four kringle domains, and a serine proteaselike ␤-chain.
14 Therefore, NK4 is a variant form of HGF, comprising the N-terminal and subsequent four kringle domains of HGF. 5 As NK4 retains the binding capacity to the HGF receptor, c-Met, it competes with HGF 6 and is known to inhibit the migration-facilitating activity of HGF in vitro. [6] [7] [8] [9] Peritoneal dissemination is a critical step for the progression of ovarian cancer and the most frequent mode of recurrence in patients. The aim of this study was to further investigate the dissemination-suppressing activity of NK4 in ovarian cancer. In this report, we demonstrated the consequences of NK4 expression in ovarian cancer cells. NK4 suppressed cell migration in vitro without affecting cell growth. In in vivo experiments, ascites formation was inhibited and the survival time was significantly extended. These actions of NK4 are consistent with HGF antagonist and suggest a novel gene therapy of NK4 that targets control of peritoneal dissemination of ovarian cancer.
Recently, tumor dormancy therapy, in which cancer growth is blocked indirectly by inhibiting angiogenesis from the host rather than by direct killing of cancer cells, is drawing attention. Anti-angiogenic substances such as angiostatin 15 and endostatin 16 have been widely known, and basic research toward gene therapy using these genes has been performed. [17] [18] [19] [20] However, there have been no therapeutic approaches using these substances for ovarian cancer. Although we did not evaluate anti-angiogenic actions of NK4 in this study, NK4 was shown to suppress the angiogenic effects of VEGF and bFGF. 21 Therefore, gene therapy using NK4 may also be effective as a tumor dormancy therapy. Currently, we are also studying the effects of soluble Flt-1, which can block the activity of VEGF.
Cancer gene therapy using a tumor suppressor gene or suicide gene requires direct transduction of cancer cells with the therapeutic gene. The efficacy of this strategy is limited because no vector system is available for transducing all cancer cells. In this study, we evaluated tumorsuppressive activity of the NK4 gene which was introduced into ovarian cancer cells ex vivo, and significant suppression in migration was observed when the ratio of NK4 transduced cells was 25% or more of the total cells.
Therefore, NK4 gene therapy may be effective in preventing peritoneal dissemination if ovarian cancer cells were partially transduced. On the other hand, for clinical application of NK4 gene therapy, it is not necessary to limit transduction to cancer cells, because NK4 is a secretory protein. Possible candidate tissue is a skeletal muscle. Muscle cells have already been demonstrated to secrete soluble factors after transduction with adenoassociated virus vectors. 22 However, to prevent the possible adverse effects, it would be better to express NK4 locally in the body. Therefore, as a target tissue, peritoneum would be a reasonable choice for transduction. We are currently exploring the methods for introducing genes to peritoneal cells.
Materials and methods
Plasmid construction and transfection into HRA cell line HRA, the human ovarian serous carcinoma cell line, was provided by Dr Y Kikuchi, and was maintained as described.
23 Cloned NK4 cDNA was inserted into the Gene Therapy SmaI site of pCMV-IRES-bsr vector. 24 pCMV-NK4-IRESbsr and the control vector pCMV-luciferase (LUC)-IRESbsr 24 encoding LUC were transfected into HRA cells by the standard calcium phosphate precipitation method. 25 The cells were selected in the presence of 10 g/ml blasticidin S hydrochloride (Funakoshi, Tokyo, Japan). Resistant clones were obtained after 4 weeks, and HRA/NK4 and HRA/LUC were obtained. The cells were subsequently maintained in the presence of 10 g/ml blasticidin S hydrochloride.
Western blotting HRA, HRA/LUC and HRA/NK4, 5 × 10 5 cells each, were plated in 6-cm plastic dishes and cultured in 2% serumsupplemented DMEM. After 24 h, the culture supernatants were subjected to electrophoresis. Western blotting was performed under standard procedures 26 utilizing anti-HGF polyclonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and the ECL detection system (Amersham Pharmacia Biotech, Aylesbury, UK).
In vitro cell growth kinetics HRA, HRA/LUC and HRA/NK4, 1 × 10 5 cells each, were plated in 6-cm plastic dishes and cultured in 10% serumsupplemented DMEM. Every 24 h, the cells were dislodged using 0.05% trypsin-EDTA and counted by a hemocytometer.
In vitro scratch wound healing assay Cell migration was measured by the in vitro scratch wound healing assay. 27 Monolayer cells were scratched with a sterile pipette tip in 3.5-cm plastic dishes, and after 24 h of culture in 2% serum-supplemented DMEM, the cell migration was evaluated by counting cells that migrated from the wound edge. Moreover, HRA/NK4 culture supernatant was added to HRA/LUC, and the cell migration activity was examined. Furthermore, HRA/NK4 were mixed with the control cells at different ratios (100%, 50%, 25%, 12.5%, 6.25%, 0%) and the effects evaluated upon migration.
In vivo tumor growth
Female BALB/c nude mice at 6-8 weeks of age (Japan Clea Laboratories, Tokyo, Japan) were used in the experiment. All of the animal experiments were performed under the guidelines of Jichi Medical School. HRA, HRA/LUC and HRA/NK4, 5 × 10 6 cells each, were subcutaneously transplanted on the backs of the mice. One week after transplantation, two dimensions of the tumors were measured using a caliper. The tumor volume was estimated by the equation: (width) 2 × (length) × 1/2. The growth curve was plotted and the doubling time was calculated from the growth curve.
In vivo peritoneal dissemination HRA, HRA/LUC and HRA/NK4, 5 × 10 6 cells each, were intraperitoneally injected in mice. Eight days after intraperitoneal injection, the mice were killed using diethylether and laparotomized, and the numbers of peritoneal tumors were measured.
Survival rate of mice injected with cancer cells
HRA, HRA/LUC and HRA/NK4, 5 × 10 6 cells each, were intraperitoneally injected in mice. The mice were maintained until death from ascites formation under a pathogen-free environment. After injection of the cells, survival of the mice was monitored twice daily. The survival rate was calculated by the Kaplan-Meier method.
Statistical analysis
All experiments were independently repeated three times or more. Significance of difference was analyzed by unpaired Student's t test and analysis of variance. The survival rates were analyzed by the generalized Wilcoxon and long-rank tests. A P value Ͻ0.05 was defined as statistically significant.
